Safety and efficacy of TBI-0301 gene-transduced donor lymphocyte infusion in patients with hematological malignancy experiencing recurrence/relapse or aggravation after allogeneic hematopoietic stem-cell transplantation
Phase of Trial: Phase I
Latest Information Update: 20 May 2016
At a glance
- Drugs Nalotimagene-carmaleucel (Primary)
- Indications Haematological malignancies; Leukaemia
- Focus Pharmacokinetics
- Sponsors Takara Bio
- 31 Mar 2013 Status changed from recruiting to discontinued.
- 23 Nov 2008 New trial record.